Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. OncoTherapy Science's annualized net income for the quarter that ended in Mar. 2026 was 円-711.0 Mil. OncoTherapy Science's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円1,894.0 Mil. Therefore, OncoTherapy Science's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -37.54%.
The historical rank and industry rank for OncoTherapy Science's Return-on-Tangible-Equity or its related term are showing as below:
TSE:4564'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -213.12 Med: -56.38 Max: -25.9
Current: -60.48
During the past 13 years, OncoTherapy Science's highest Return-on-Tangible-Equity was -25.90%. The lowest was -213.12%. And the median was -56.38%.
TSE:4564's Return-on-Tangible-Equity is ranked worse than 59.17% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs TSE:4564: -60.48
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
OncoTherapy Science Return-on-Tangible-Equity Related Terms
OncoTherapy Science Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, OncoTherapy Science's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -37.54% mean?
OncoTherapy Science (TSE:4564) has a Return-on-Tangible-Equity of -37.54% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #710 out of 1200 companies in the Biotechnology industry, placing it in the top 59.2%.
Is OncoTherapy Science's Return-on-Tangible-Equity too high?
OncoTherapy Science's current Return-on-Tangible-Equity is -37.54%. Based on the distribution chart, OncoTherapy Science ranks #710 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #710 out of 1200 companies for Return-on-Tangible-Equity. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Return-on-Tangible-Equity is -37.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円16.92, compared to a current price of 円20.00 — trading 18.2% above its estimated fair value. The current Return-on-Tangible-Equity is -37.54%. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Return-on-Tangible-Equity is -37.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円20.00 is trading 18.2% above its estimated GF Value™ of 円16.92.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Return-on-Tangible-Equity: -37.54%
GF Value™: 円16.92 vs. price of 円20.00 (18.2% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
